封面
市場調查報告書
商品編碼
1231386

成長因子(血液·組織)的全球市場

Growth Factors (Blood and Tissue)

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 223 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

成長因子(血液·組織)的全球市場到2030年將達到1,015億美元

在COVID-19後改變的商務環境中,2022年估算為403億美元的成長因子(血液·組織)的全球市場到2030年將達到1015億美元,在2022年~2030年間預計將以年複合成長率12.2%增長。本報告所分析的市場區隔之一的干擾素年複合成長率將記錄15.1%,到分析期間結束時將達到782億美元。考慮疫情過後的復甦,細胞聚落刺激因子領域今後8年的年複合成長率修正為-0.4%。

美國市場佔110億美元,中國則將以年複合成長率18.4%的速度成長

美國的成長因子(血液·組織)市場在2022年估算為達到110億美元。作為世界第2大經濟大國的中國,在分析期間的2022年~2030年間年複合成長率預計將為18.4%,2030年達到262億美元的市場規模。其他熱門的地區市場有日本和加拿大,在分析期間的2022年~2030年間預計將各以6.9%和11.1%的速度成長。歐洲市場中,德國將以年複合成長率8.4%成長。

調查對像企業範例

  • Amgen, Inc.
  • Bayer HealthCare Pharmaceuticals, Inc.
  • Biocon Ltd.
  • Biogen, Inc.
  • Biopharm GmbH
  • Bolder BioTechnology, Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • Genentech, Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • Lonza Group
  • Merck Serono
  • PeproTech, Inc.
  • Reliance GeneMedix Plc
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Scil Proteins GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Ltd.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

第4章 競爭

簡介目錄
Product Code: MCP-1217

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Growth Factors (Blood and Tissue) Market to Reach $101.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Growth Factors (Blood and Tissue) estimated at US$40.3 Billion in the year 2022, is projected to reach a revised size of US$101.5 Billion by 2030, growing at aCAGR of 12.2% over the period 2022-2030. Interferons, one of the segments analyzed in the report, is projected to record 15.1% CAGR and reach US$78.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Colony Stimulating Factors segment is readjusted to a revised -0.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $11 Billion, While China is Forecast to Grow at 18.4% CAGR

The Growth Factors (Blood and Tissue) market in the U.S. is estimated at US$11 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$26.2 Billion by the year 2030 trailing a CAGR of 18.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 11.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Select Competitors (Total 101 Featured):

  • Amgen, Inc.
  • Bayer HealthCare Pharmaceuticals, Inc.
  • Biocon Ltd.
  • Biogen, Inc.
  • Biopharm GmbH
  • Bolder BioTechnology, Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • Genentech, Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • Lonza Group
  • Merck Serono
  • PeproTech, Inc.
  • Reliance GeneMedix Plc
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Scil Proteins GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Growth Factors (Blood and Tissue) - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • An Introduction to Growth Factors
    • Interferons
    • Colony Stimulating Factors
    • Erythropoietins
    • Interleukins
    • Global Market Prospects & Outlook
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Adoption of Growth Factors in Pharmaceutical & Biotech Companies
    • Global Spending on Pharmaceuticals (in US$ Billion)
    • Life Science Research and Clinical Trials for Novel Drug Development and Therapies to Boost Market
    • Cell Culture-based Research Fuels Need for Growth Factors
    • Global Cell Culture Market Size (in US$ Billion) for the Years 2020, 2022 and 2025
    • Expanding Stem Cell Biology Applications & Focus on Stem Cell Research Initiatives Spur Demand for Growth Factors
    • Rising Use of Growth Factors in Regenerative Medicines and Tissue Regeneration
    • Global Regenerative Medicine Market Size (US$ Billion) for 2020, 2022 & 2025
    • Global Tissue Engineering Market Size (US$ Billion) for 2020, 2022 & 2025
    • Increasing Funding for Life Science Research Underpinning Gains
    • Funding in Life Sciences industry: Number of Deals for 2010 to 2020
    • Global Funding Rounds ($100 Million+) in Life Science-Related Sectors: 2016-2020
    • Growth Factors Find Increasing Role in Wound Healing and Skin Regeneration
    • Oncology Research Focus Drives Importance of Growth Factors
    • Erythropoietin (EPO) Market: Potential Opportunities from Anemia in CKD and Cancer Patients
    • Interferons Market to Benefit from Rising Demand for Specialized Therapies
    • Growing Importance of Interferons in Viral Infections
    • Colony Stimulating Factors (CSFs) Market
    • Interleukins Market: Applications to Drive Market Growth
    • Neurotrophic Therapeutics: Opportunities in Store
    • Blood Growth Factors Market
    • Role of Growth Factors in Multiple Sclerosis Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Interferons by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Erythropoietins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Erythropoietins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Interleukins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Interleukins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Interleukins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Other Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Other Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 19: World Growth Factors (Blood and Tissue) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • JAPAN
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • CHINA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: China 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • EUROPE
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • FRANCE
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: France 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • GERMANY
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • INDIA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: India 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030
  • AFRICA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2023 & 2030

IV. COMPETITION